News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
BioMarin's ENPP1 drug fails key trial goal, clouding approval path
BioMarin's acquired treatment for ENPP1 deficiency missed a regulatory endpoint in clinical trials, raising questions about its path to market approval and the deal's value.
Acceleron founders launch IPF biotech startup with $30M Series A
Oorja Bio raised $30 million from Westlake to develop treatments for idiopathic pulmonary fibrosis, a rare lung disease. The startup is led by former Acceleron executives who previously brought Winrevair to market.
Paragon Therapeutics moves migraine drugs via reverse merger strategy
Paragon Therapeutics announced a reverse merger for its migraine drug offshoot Tuesday, continuing the company's pattern of using this structure for biotech spinouts. Details on timing and valuation remain unclear.
Trump adds 600+ generics to TrumpRx direct-to-consumer platform
The Trump administration expanded its TrumpRx pharmacy portal with more than 600 generic medicines. Here's what the move signals about direct pharma distribution.
GHO Capital and CBC Group merge to manage $21B in healthcare assets
European healthcare investor GHO Capital and asset manager CBC Group are combining operations. The deal creates what the firms claim is the largest healthcare-focused investment platform in Europe.
Parabilis Files for IPO as 12th Biotech Listing This Year
Harvard-spun Parabilis Medicines, founded by Greg Verdine, plans to go public in 2024. The decade-old undruggable-focused biotech joins a surge in drug developer IPOs after years of drought.
Medical Affairs Teams Struggle to Measure Impact Beyond Activity
Medical Affairs groups are improving internal alignment but failing to tie their work to measurable behavior change among doctors and patients. A new report identifies the measurement gaps holding teams back.
Mayo Clinic AI Tool Identified a Rare Disease Treatment in Days, Not Years
A newborn with a chromosome 10 deletion faced severe muscle paralysis. An NIH-funded AI knowledge graph found Klonopin—a widely available drug—as a potential treatment. The results came fast enough to change her life.
OpenEvidence courts hospitals after building 650K-doctor user base
The AI clinical decision tool raised $12B on a free-to-physicians model. Now it's pitching health systems directly—signaling a shift away from ad-only revenue.
Hubble.GOLF Centralizes Fragmented Junior Golf Into Operating System
Cory Powell's startup treats competitive golf as a data and logistics problem, bundling tournament discovery, travel booking, and recruiting visibility into one platform for families managing junior athletes.
Agroclimatica Claims Only Climate Risk Tool for Farm Loans, Eyes Latin America
Lars Moller, CEO of Agroclimatica, says the startup quantifies climate and production risk for agricultural lenders with no competitors globally. The company targets 500M farms but focuses expansion on Latin America.
Kubegrade automates Kubernetes fixes that teams now solve manually
Kubegrade CEO Tim Grassin explains how the startup fills a $12B gap: detecting cluster issues is solved, but automatic remediation via GitOps pull requests remains rare.